个体化自体新抗原特异性T细胞疗法治疗转移性黑色素瘤:一项1期试验
针对免疫检查点阻断(ICB)或BRAF靶向治疗难治的晚期黑色素瘤患者,设计个体化新抗原特异性自体T细胞产品BNT221,在3+3剂量探索研究中设两个剂量水平(DL1:1×10^8-1×10^9个细胞,3例;DL2:2×10^9-1×10^10个细胞,6例),共9例。BNT221在两个剂量水平均耐受良好,未观察到≥3级剂量限制性毒性,确定5.0×10^8-1.0×10^10个细胞用于进一步研究;6例最佳总体疗效为疾病稳定,其中4例报告肿瘤缩小(≤20%)。
要点
- BNT221为源自外周血的个体化新抗原特异性自体T细胞产品,所有入组患者均成功制备。
- 两个剂量水平均耐受良好,未观察到≥3级剂量限制性毒性,无细胞因子释放、免疫效应细胞相关神经毒性或巨噬细胞活化综合征报告。
- 9例中6例最佳总体疗效为疾病稳定,其中4例报告肿瘤缩小(≤20%)。
核心结论
- 结果为该新抗原特异性过继T细胞疗法提供了关键见解,并证明这一新治疗方法的可行性。
研究设计与样本
- 3+3剂量探索研究,设两个剂量水平:DL1为1×10^8-1×10^9个细胞(3例),DL2为2×10^9-1×10^10个细胞(6例)。
- 纳入局部晚期或转移性黑色素瘤患者,要求ICB后疾病进展、具有可测量病灶(实体瘤疗效评价标准1.1版),并在适当情况下接受过BRAF靶向治疗。
- 报告已完成单药治疗臂的未预先设定的最终结果,共9例。
- 主要和次要目标为评估安全性、最高耐受剂量和抗肿瘤活性。
主要发现
- 所有入组患者均成功生成药品。
- BNT221在两个剂量水平均耐受良好,未观察到归因于T细胞产品的≥3级剂量限制性毒性。
- 未报告细胞因子释放综合征、免疫效应细胞相关神经毒性综合征或巨噬细胞活化综合征。
- 确定5.0×10^8-1.0×10^10个细胞用于进一步研究开展。
- 6例最佳总体疗效为疾病稳定,其中4例报告肿瘤缩小(≤20%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New treatment approaches are warranted for patients with advanced melanoma refractory to immune checkpoint blockade (ICB) or BRAF-targeted therapy. We designed BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, and tested this in a 3 + 3 dose-finding study with two dose levels (DLs) in patients with locally advanced or metastatic melanoma, disease progression after ICB, measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1) and, where appropriate, BRAF-targeted therapy. Primary and secondary objectives were evaluation of safety, highest tolerated dose and anti-tumor activity. We report here the non-pre-specified, final results of the completed monotherapy arm consisting of nine patients: three at DL1 (1 × 108-1 × 109 cells) and six at DL2 (2 × 109-1 × 1010 cells). Drug products (DPs) were generated for all enrolled patients. BNT221 was well tolerated across both DLs, with no dose-limiting toxicities of grade 3 or higher attributed to the T cell product observed. Specifically, no cytokine release, immune effector cell-associated neurotoxicity or macrophage activation syndromes were reported. A dose of 5.0 × 108-1.0 × 1010 cells was identified for further study conduct. Six patients showed stable disease as best overall response, and tumor reductions (≤20%) were reported for four of these patients. In exploratory analyses, multiple mutant-specific CD4+ and CD8+ T cell responses were generated in each DP. These were cytotoxic, polyfunctional and expressed T cell receptors with broad functional avidities. Neoantigen-specific clonotypes were detected after treatment in blood and tumor. Our results provide key insights into this neoantigen-specific adoptive T cell therapy and demonstrate proof of concept for this new therapeutic approach. ClinicalTrials.gov registration: NCT04625205 .
引用
- Borgers JSW, Lenkala D, Kohler V, et al. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Nat Med. 2025. PMID: 39753970. doi:10.1038/s41591-024-03418-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。